← Back to Analyst Consensus 
VIR Buy
Vir Biotechnology, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 7, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 11, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Jun 3, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Mar 4, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Feb 25, 2026 | Barclays | maintain | Overweight → Overweight | $30 | 53% |
| Feb 24, 2026 | Morgan Stanley | maintain | Overweight → Overweight | $24 | 54% |
| Feb 24, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | $18 | 58% |
| Feb 24, 2026 | Needham | maintain | Buy → Buy | $18 | 50% |
| Feb 9, 2026 | Needham | reiterate | Buy → Buy | $14 | 50% |
| Dec 30, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Sep 15, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $15 | 44% |
| Sep 3, 2025 | Evercore ISI Group | initiate | — → Outperform | $12 | 58% |
| Aug 27, 2025 | B of A Securities | upgrade | Neutral → Buy | $14 | 53% |
| Jul 11, 2025 | Raymond James | initiate | — → Outperform | $12 | 54% |
| May 22, 2025 | Needham | reiterate | Buy → Buy | $14 | 50% |
| May 12, 2025 | Needham | maintain | Buy → Buy | $14 | 50% |
| Apr 17, 2025 | Goldman Sachs | maintain | Buy → Buy | $21 | 54% |
| Feb 28, 2025 | Barclays | maintain | Overweight → Overweight | $31 | 53% |
| Feb 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Feb 27, 2025 | Needham | reiterate | Buy → Buy | $19 | 50% |
| Jan 31, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Jan 13, 2025 | Leerink Partners | maintain | Outperform → Outperform | $20 | 51% |
| Jan 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Jan 9, 2025 | Morgan Stanley | upgrade | Equal-Weight → Overweight | $20 | 54% |
| Jan 9, 2025 | JP Morgan | maintain | Neutral → Neutral | $14 | 55% |
| Nov 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Nov 20, 2024 | Needham | reiterate | Buy → Buy | $19 | 50% |
| Nov 4, 2024 | Barclays | maintain | Overweight → Overweight | $26 | 53% |
| Nov 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Nov 1, 2024 | Needham | reiterate | Buy → Buy | $19 | 50% |
| Aug 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Aug 2, 2024 | Barclays | maintain | Overweight → Overweight | $28 | 53% |
| Jun 6, 2024 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $15 | 54% |
| Jun 5, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Jun 5, 2024 | Needham | maintain | Buy → Buy | $19 | 50% |
| May 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| May 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| May 3, 2024 | JP Morgan | maintain | Neutral → Neutral | $12 | 55% |
| May 3, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Mar 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Feb 23, 2024 | JP Morgan | maintain | Neutral → Neutral | $10 | 55% |
| Feb 14, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $110 | 44% |
| Jan 29, 2024 | JP Morgan | downgrade | Overweight → Neutral | $9 | 55% |
| Jan 23, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $85 | 44% |
| Nov 3, 2023 | Needham | maintain | Buy → Buy | $15 | 50% |
| Sep 8, 2023 | B of A Securities | downgrade | Buy → Neutral | $14 | 53% |
| Aug 7, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $95 | 44% |
| Aug 4, 2023 | Needham | reiterate | Buy → Buy | $22 | 50% |
| Jul 21, 2023 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $15 | 54% |
| Jul 21, 2023 | Goldman Sachs | maintain | Buy → Buy | $28 | 54% |
Price Target Trend
Apr 23, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days